메뉴 건너뛰기




Volumn 44, Issue 2, 2013, Pages 182-189

Phase i study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas

Author keywords

5 Fluorouracil; Gemcitabine; Irinotecan; Oxaliplatin; Pancreatic cancer; Phase I

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX;

EID: 84887080214     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-012-9466-2     Document Type: Article
Times cited : (2)

References (44)
  • 2
    • 42349093032 scopus 로고    scopus 로고
    • Metaanalysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
    • doi:10.1186/ 1471-2407-8-82
    • Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Metaanalysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82. doi:10.1186/ 1471-2407-8-82.
    • (2008) BMC Cancer , vol.8 , pp. 82
    • Heinemann, V.1    Boeck, S.2    Hinke, A.3    Labianca, R.4    Louvet, C.5
  • 4
    • 68949114505 scopus 로고    scopus 로고
    • Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-min infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group
    • doi:10.1200/JCO.2008.20.9007
    • Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson 3rd AB. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-min infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-85. doi:10.1200/JCO.2008.20.9007.
    • (2009) J Clin Oncol , vol.27 , pp. 3778-3785
    • Poplin, E.1    Feng, Y.2    Berlin, J.3    Rothenberg, M.L.4    Hochster, H.5    Mitchell, E.6    Alberts, S.7    O'Dwyer, P.8    Haller, D.9    Catalano, P.10    Cella, D.11    Benson III, A.B.12
  • 5
    • 4644327989 scopus 로고    scopus 로고
    • Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
    • doi:10.1200/JCO.2004.12.082
    • Rocha Lima CM, Green MR, Rotche R, Miller Jr WH, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-83. doi:10.1200/JCO.2004.12.082.
    • (2004) J Clin Oncol , vol.22 , pp. 3776-3783
    • Rocha Lima, C.M.1    Green, M.R.2    Rotche, R.3    Miller Jr., W.H.4    Jeffrey, G.M.5    Cisar, L.A.6    Morganti, A.7    Orlando, N.8    Gruia, G.9    Miller, L.L.10
  • 6
    • 34249933404 scopus 로고    scopus 로고
    • Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    • National Cancer Institute of Canada Clinical Trials Group, doi:10.1200/JCO.2006.07.9525
    • Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6. doi:10.1200/JCO.2006.07.9525.
    • (2007) J Clin Oncol , vol.25 , pp. 1960-1966
    • Moore, M.J.1    Goldstein, D.2    Hamm, J.3    Figer, A.4    Hecht, J.R.5    Gallinger, S.6    Au, H.J.7    Murawa, P.8    Walde, D.9    Wolff, R.A.10    Campos, D.11    Lim, R.12    Ding, K.13    Clark, G.14    Voskoglou-Nomikos, T.15    Ptasynski, M.16    Parulekar, W.17
  • 7
    • 79955921754 scopus 로고    scopus 로고
    • FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med
    • doi:10.1056/NEJMoa1011923
    • Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;N Engl J Med 364:1817-25. doi:10.1056/NEJMoa1011923.
    • (2011) N Engl J Med , vol.364 , pp. 1817-1825
    • Conroy, T.1    Desseigne, F.2    Ychou, M.3    Bouche, O.4    Guimbaud, R.5    Becouarn, Y.6    Adenis, A.7
  • 8
    • 33846702197 scopus 로고    scopus 로고
    • Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer
    • doi:10.1097/CAD.0b013e3280121334
    • Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Anticancer Drugs. 2007;18:263-71. doi:10.1097/CAD.0b013e3280121334.
    • (2007) Anticancer Drugs , vol.18 , pp. 263-271
    • Goel, A.1    Grossbard, M.L.2    Malamud, S.3    Homel, P.4    Dietrich, M.5    Rodriguez, T.6    Mirzoyev, T.7    Kozuch, P.8
  • 10
    • 0000460127 scopus 로고    scopus 로고
    • Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel
    • Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52:1855-65.
    • (1996) Biochem Pharmacol , vol.52 , pp. 1855-1865
    • Rixe, O.1    Ortuzar, W.2    Alvarez, M.3    Parker, R.4    Reed, E.5    Paull, K.6    Fojo, T.7
  • 12
    • 0033786068 scopus 로고    scopus 로고
    • Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases
    • Kornmann M, Fakler H, Butzer U, Beger HG, Link KH. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res. 2000;20:3259-64.
    • (2000) Anticancer Res , vol.20 , pp. 3259-3264
    • Kornmann, M.1    Fakler, H.2    Butzer, U.3    Beger, H.G.4    Link, K.H.5
  • 13
    • 0030722949 scopus 로고    scopus 로고
    • Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
    • Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs. 1997;8:876-85.
    • (1997) Anticancer Drugs , vol.8 , pp. 876-885
    • Raymond, E.1    Buquet-Fagot, C.2    Djelloul, S.3    Mester, J.4    Cvitkovic, E.5    Allain, P.6    Louvet, C.7    Gespach, C.8
  • 14
    • 0032990022 scopus 로고    scopus 로고
    • Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
    • Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999;44:117-23.
    • (1999) Cancer Chemother Pharmacol , vol.44 , pp. 117-123
    • Faivre, S.1    Raymond, E.2    Woynarowski, J.M.3    Cvitkovic, E.4
  • 15
    • 0032905667 scopus 로고    scopus 로고
    • Cellular pharmacology of the combination of the DNA topoisomerase i inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin
    • Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999;5:1189-96.
    • (1999) Clin Cancer Res , vol.5 , pp. 1189-1196
    • Zeghari-Squalli, N.1    Raymond, E.2    Cvitkovic, E.3    Goldwasser, F.4
  • 17
    • 79960019683 scopus 로고    scopus 로고
    • Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
    • doi:10.1016/j.ejca.2011.04.011
    • Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676-81. doi:10.1016/j.ejca.2011.04.011.
    • (2011) Eur J Cancer , vol.47 , pp. 1676-1681
    • Pelzer, U.1    Schwaner, I.2    Stieler, J.3    Adler, M.4    Seraphin, J.5    Dorken, B.6    Riess, H.7    Oettle, H.8
  • 18
    • 77949699034 scopus 로고    scopus 로고
    • Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: A report from the clinical trial design task force of the national cancer institute investigational drug steering committee
    • doi:10.1158/1078-0432.CCR-09-1961
    • Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010;16:1726-36. doi:10.1158/1078-0432.CCR-09-1961.
    • (2010) Clin Cancer Res , vol.16 , pp. 1726-1736
    • Ivy, S.P.1    Siu, L.L.2    Garrett-Mayer, E.3    Rubinstein, L.4
  • 20
    • 12244287645 scopus 로고    scopus 로고
    • An open phase i study assessing the feasibility of the triple combination: Oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors
    • Ychou M, Conroy T, Seitz JF, Gourgou S, Hua A, Mery-Mignard D, Kramar A. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2003;14:481-9.
    • (2003) Ann Oncol , vol.14 , pp. 481-489
    • Ychou, M.1    Conroy, T.2    Seitz, J.F.3    Gourgou, S.4    Hua, A.5    Mery-Mignard, D.6    Kramar, A.7
  • 21
    • 4143148621 scopus 로고    scopus 로고
    • Dosefinding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients
    • doi:10.1093/ annonc/mdh259
    • Cals L, Rixe O, Francois E, Favre R, Merad L, Deplanque G, Laadem A, Juin P, Bereder JM, Bernardini D, Herait P. Dosefinding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol. 2004;15:1018-24. doi:10.1093/ annonc/mdh259.
    • (2004) Ann Oncol , vol.15 , pp. 1018-1024
    • Cals, L.1    Rixe, O.2    Francois, E.3    Favre, R.4    Merad, L.5    Deplanque, G.6    Laadem, A.7    Juin, P.8    Bereder, J.M.9    Bernardini, D.10    Herait, P.11
  • 23
    • 0036682041 scopus 로고    scopus 로고
    • Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
    • Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson 3rd AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-5.
    • (2002) J Clin Oncol , vol.20 , pp. 3270-3275
    • Berlin, J.D.1    Catalano, P.2    Thomas, J.P.3    Kugler, J.W.4    Haller, D.G.5    Benson III, A.B.6
  • 30
    • 63849329062 scopus 로고    scopus 로고
    • Second-line therapy in refractory pancreatic cancer. Results of a phase II study
    • doi:10.1159/000197769
    • Pelzer U, Stieler J, Roll L, Hilbig A, Dorken B, Riess H, Oettle H. Second-line therapy in refractory pancreatic cancer. Results of a phase II study. Onkologie. 2009;32:99-102. doi:10.1159/000197769.
    • (2009) Onkologie , vol.32 , pp. 99-102
    • Pelzer, U.1    Stieler, J.2    Roll, L.3    Hilbig, A.4    Dorken, B.5    Riess, H.6    Oettle, H.7
  • 31
    • 1842450186 scopus 로고    scopus 로고
    • Phase i dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors
    • Rachamalla R, Malamud S, Grossbard ML, Mathew S, Dietrich M, Kozuch P. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. Anticancer Drugs. 2004;15:211-7.
    • (2004) Anticancer Drugs , vol.15 , pp. 211-217
    • Rachamalla, R.1    Malamud, S.2    Grossbard, M.L.3    Mathew, S.4    Dietrich, M.5    Kozuch, P.6
  • 32
    • 79952806073 scopus 로고    scopus 로고
    • Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer (MPC)
    • 2011 Gastrointestinal Cancers Symposium
    • Bendell SB JC, Green MR, Willey J, Lemke KE, Marshall J. Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer (MPC). J Clin Oncol. 2011;29:286. 2011 Gastrointestinal Cancers Symposium.
    • (2011) J Clin Oncol , vol.29 , pp. 286
    • Bendell, S.B.J.C.1    Green, M.R.2    Willey, J.3    Lemke, K.E.4    Marshall, J.5
  • 33
    • 83355169644 scopus 로고    scopus 로고
    • Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer
    • doi:10.1111/j.1743-7563.2011.01390.x
    • Mitchell PL, Broad A, Rosenthal MA, Galettis P, Abraham R, Burns I, Clarke S, Milner A, Diiulio J, Links M. Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. Asia Pac J Clin Oncol. 2011;7:376-84. doi:10.1111/j.1743-7563.2011. 01390.x.
    • (2011) Asia Pac J Clin Oncol , vol.7 , pp. 376-384
    • Mitchell, P.L.1    Broad, A.2    Rosenthal, M.A.3    Galettis, P.4    Abraham, R.5    Burns, I.6    Clarke, S.7    Milner, A.8    Diiulio, J.9    Links, M.10
  • 35
    • 58549097306 scopus 로고    scopus 로고
    • Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatininduced DNA damage
    • doi:10.1093/nar/gkn910
    • Wilson PM, Fazzone W, LaBonte MJ, Lenz HJ, Ladner RD. Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatininduced DNA damage. Nucleic Acids Res. 2009;37:78-95. doi:10.1093/nar/gkn910.
    • (2009) Nucleic Acids Res , vol.37 , pp. 78-95
    • Wilson, P.M.1    Fazzone, W.2    Labonte, M.J.3    Lenz, H.J.4    Ladner, R.D.5
  • 36
    • 0031755917 scopus 로고    scopus 로고
    • Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: Preclinical data
    • Fischel JL, Etienne MC, Formento P, Milano G. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res. 1998;4:2529-35.
    • (1998) Clin Cancer Res , vol.4 , pp. 2529-2535
    • Fischel, J.L.1    Etienne, M.C.2    Formento, P.3    Milano, G.4
  • 38
    • 0142121290 scopus 로고    scopus 로고
    • Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma
    • doi:10.1200/JCO.2003.09.140
    • Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-8. doi:10.1200/JCO.2003.09.140.
    • (2003) J Clin Oncol , vol.21 , pp. 3402-3408
    • Tempero, M.1    Plunkett, W.2    Ruiz Van Haperen, V.3    Hainsworth, J.4    Hochster, H.5    Lenzi, R.6    Abbruzzese, J.7
  • 39
    • 43749093441 scopus 로고    scopus 로고
    • Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer
    • doi:10.1200/JCO.2007.13.3934
    • Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2099-105. doi:10.1200/JCO.2007.13.3934.
    • (2008) J Clin Oncol , vol.26 , pp. 2099-2105
    • Gamelin, E.1    Delva, R.2    Jacob, J.3    Merrouche, Y.4    Raoul, J.L.5    Pezet, D.6    Dorval, E.7    Piot, G.8    Morel, A.9    Boisdron-Celle, M.10
  • 40
    • 66849118694 scopus 로고    scopus 로고
    • Dose escalation methods in phase i cancer clinical trials
    • doi:10.1093/jnci/djp079
    • Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101:708-20. doi:10.1093/jnci/djp079.
    • (2009) J Natl Cancer Inst , vol.101 , pp. 708-720
    • Le Tourneau, C.1    Lee, J.J.2    Siu, L.L.3
  • 41
    • 80053195495 scopus 로고    scopus 로고
    • Looking to the future: Biomarkers in the management of pancreatic adenocarcinoma
    • doi:10.3390/ijms12095895
    • Spratlin JL, Mulder KE. Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. Int J Mol Sci. 2011;12:5895-907. doi:10.3390/ijms12095895.
    • (2011) Int J Mol Sci , vol.12 , pp. 5895-5907
    • Spratlin, J.L.1    Mulder, K.E.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.